Related Experiment Video
Updated: Jul 19, 2026
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic
Ji Eun Lee1, Yu Lian Zhang2, Doo Hee Han2
1Department of Otorhinolaryngology-Head and Neck Surgery, Chosun University College of Medicine, Gwangju, Korea.
Purpose:
Peroxisome proliferator-activated receptor γ (PPAR-γ) has been shown to play an important role in the control of inflammatory responses acting on macrophages, mast cells, T cells and eosinophils. A novel PPAR-γ ligand, KR62980 have been recently focused on due to the lower undesirable effects than other PPAR-γ ligands such as rosiglitazone and pioglitazone. The present study was aimed to investigate the effects of KR62980 on nasal symptoms and immunopathological profiles in allergic nasal mucosa in murine allergic rhinitis model.
Methods:
BALB/c mice were sensitized and challenged intranasally with ovalbumin (OVA). KR62980 was administered intraperitoneally or orally 3 hours before each intranasal OVA challenge.
Results:
Administration of KR62980 significantly decreased the number of nasal rubbing, nasal sneezing, ova-specific IgE and total IgE in serum, secretion of Interleukin (IL)-4, IL-5, and IL-17 from the spleen and eosinophilic infiltration in the nasal mucosa. KR62980 decreased the expression of IL-4, IL-5 and IL-10 mRNAs in the nasal mucosal tissue, while, it elevated the level of IL-10 and IFN-γ in splenocyte culture. KR62980 seemed to decrease IL-17 level in local and systemic level even though it did not reach to statistical significance. The anti-inflammatory effect was more definite when the KR62980 was administered intraorally than intraperitoneally.
Conclusions:
A novel PPAR-γ ligand, KR62980 can attenuate OVA-induced allergic inflammation in mice mainly through modulation of Th2 cytokines. This finding suggests that PPAR-γ might have a role in the treatment of allergic rhinitis.
Insights
The novel PPAR-γ ligand KR62980 effectively reduced allergic rhinitis symptoms and inflammation in mice. Oral administration showed a more pronounced anti-inflammatory effect, suggesting potential therapeutic benefits for allergic rhinitis.
Area of Science:
- Immunology
- Pharmacology
- Allergy Research
Background:
- Peroxisome proliferator-activated receptor γ (PPAR-γ) plays a key role in regulating inflammatory responses.
- Novel PPAR-γ ligands, like KR62980, are being investigated for reduced side effects compared to existing treatments.
- Allergic rhinitis involves complex immune responses in the nasal mucosa.
Purpose of the Study:
- To evaluate the efficacy of the novel PPAR-γ ligand KR62980 in a murine model of allergic rhinitis.
- To assess the impact of KR62980 on nasal symptoms and key immunopathological markers.
- To compare the anti-inflammatory effects of different administration routes (oral vs. intraperitoneal) of KR62980.
Main Methods:
- BALB/c mice were sensitized and challenged with ovalbumin (OVA) to induce allergic rhinitis.
- KR62980 was administered via intraperitoneal or oral routes prior to OVA challenges.
- Nasal symptoms, serum IgE levels, cytokine profiles (IL-4, IL-5, IL-17, IL-10, IFN-γ), and tissue eosinophil infiltration were analyzed.
Main Results:
- KR62980 significantly reduced nasal symptoms (rubbing, sneezing) and OVA-specific IgE.
- It decreased Th2 cytokines (IL-4, IL-5) and IL-17 in spleen and nasal tissue, while increasing IL-10 and IFN-γ.
- Oral administration of KR62980 demonstrated a more significant anti-inflammatory effect than intraperitoneal administration.
Conclusions:
- KR62980 effectively attenuates OVA-induced allergic inflammation in mice, primarily by modulating Th2 cytokine responses.
- The findings suggest that PPAR-γ ligands, such as KR62980, hold promise for the treatment of allergic rhinitis.
- Further research into PPAR-γ modulation could lead to novel therapeutic strategies for allergic airway diseases.
